2.58
+0.127(+5.18%)
Currency In USD
| Previous Close | 2.45 |
| Open | 2.54 |
| Day High | 2.61 |
| Day Low | 2.52 |
| 52-Week High | 6.01 |
| 52-Week Low | 1.12 |
| Volume | 72,235 |
| Average Volume | 494,301 |
| Market Cap | 50.67M |
| PE | -1.17 |
| EPS | -2.21 |
| Moving Average 50 Days | 3.02 |
| Moving Average 200 Days | 2.7 |
| Change | 0.13 |
If you invested $1000 in NRx Pharmaceuticals, Inc. (NRXP) since IPO date, it would be worth $25.52 as of November 10, 2025 at a share price of $2.45. Whereas If you bought $1000 worth of NRx Pharmaceuticals, Inc. (NRXP) shares 5 years ago, it would be worth $0.23 as of November 10, 2025 at a share price of $2.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
GlobeNewswire Inc.
2 hours ago
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.HOPE is one of the first Ampa deployments nationwide and is now deployed at multiple HOPE locati
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
GlobeNewswire Inc.
Oct 20, 2025 12:03 PM GMT
Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAc
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
GlobeNewswire Inc.
Oct 06, 2025 12:03 PM GMT
WILMINGTON, Del., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interven